Mediwound (MDWD) has released an update.
MediWound Ltd. and Teva Pharmaceutical Industries Ltd. have effectively agreed on a second amendment to their 2019 settlement agreement, which will resolve all outstanding issues related to their prior business relationship. This amendment includes a final payment of $4 million from MediWound to Teva, with conditions that include cash payment and setoff arrangements. The updated agreement reaffirms the full and final settlement of claims between the two parties and outlines the tax treatment for the payments.
For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.
